Nektar Therapeutics
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M | $199.0M | $96.4M | $194.9M |
| Accounts Receivable | — | $0 | $1.2M | $6.0M | $22.5M | $38.9M | $36.8M | $43.2M |
| Inventory | $0 | $0 | $16.1M | $19.2M | $15.8M | $15.3M | $12.7M | $11.4M |
| Total Current Assets | $266.3M | $261.3M | $330.7M | $546.0M | $795.6M | $1.14B | $1.42B | $1.44B |
| Property, Plant & Equipment | $2.1M | $3.4M | $18.9M | $32.5M | $60.5M | $59.7M | $65.7M | $48.9M |
| Goodwill | — | — | $0 | $76.5M | $76.5M | $76.5M | $76.5M | $76.5M |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.12B | $1.54B | $1.98B | $2.15B |
| Liabilities | ||||||||
| Accounts Payable | $10.8M | $11.6M | $9.8M | $13.0M | $9.7M | $22.1M | $19.2M | $5.9M |
| Total Current Liabilities | $53.5M | $61.4M | $51.3M | $68.2M | $85.2M | $115.8M | $353.9M | $82.0M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M | $461.5M | $572.0M | $432.6M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B |
| Total Stockholders' Equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M | $1.08B | $1.41B | $1.72B |